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In this issue of Cancer Cell, Haybaeck et al. unravel the role of lymphotoxin pathway in the development of
hepatocellular carcinoma (HCC). Aberrant activation of this cascade in mice livers recapitulates the stages
of fibrosis and inflammation that precedes human liver cancer, providing a novel family of potential thera-
peutic targets.Hepatocellular carcinoma (HCC) is, world-
wide, the third cause of cancer-related
death and one of the fastest growing
malignancies in terms of incidence in
Western populations (Llovet et al., 2003).
Despite recent progress, HCC is still
considered a disease with poor prognosis
because less than 30% of cases are
eligible for potential curative treatments
(e.g., surgical resection, liver transplanta-
tion, or percutaneous ablation). Recent
results of a phase III trial showed that
sorafenib, a multikinase inhibitor of
BRAF, PDGFR, and VEGFR, significantly
improved survival in patients with
advanced tumors (Llovet et al., 2008).
This pivotal study established a new stan-
dard of care for these patients and cleared
the path for the development of novel
molecular therapies for this malignancy.
Molecular bases that link inflammation
and cancer have been progressively
uncovered. Robust epidemiological data
support the role of inflammation induced
by chronic hepatitis B or C viral infections
and alcohol abuse as a key player in
HCC development. However, the exact
molecular mechanisms and gatekeepers
accounting for cellular transformation
remain elusive. In this issue of Cancer
Cell, Haybaeck et al. describe the role of
sustained lymphotoxin signaling in HCC
development (Haybaeck et al., 2009).
The authors found aberrant expression
of lymphotoxins a and b and LTb receptor
in human samples, and by applying
numerous animal models, they teased
out some relevant molecular mechanisms
of hepatitis-induced HCC. Transgenic272 Cancer Cell 16, October 6, 2009 ª2009mice overexpressing lymphotoxins a and
b in hepatocytes developed chronic
hepatitis at 9 months and HCC at 12
months, which ultimately disseminate.
To investigate the mechanisms by which
hepatitis and HCC were induced, the
authors crossed these mice with 4
different knockout mice (TNF receptor 1,
TNF receptor 2, hepatocyte IKK kinase
b, and mature B and T lymphocytes
depletion), showing that NF-kB pathway
is important for liver inflammation and
HCC development.
The identification of lymphotoxin acti-
vated signaling as key in HCC develop-
ment was confirmed by the fact that the
administration of lymphotoxin antago-
nists for 2 months in mice with chronic
hepatitis reduced inflammatory activity
and prevented the development of HCC
compared to control animals. Overall,
these data introduce lymphotoxins as
a novel family of potential targets for
HCC chemoprevention and suggest anti-
fibrotic activity by blocking lymphotoxin
signaling. In addition, it complements
previous knowledge on NF-kB involve-
ment in HCC (Karin, 2006), and supports
efforts to evaluate pharmacologic modu-
lation of this pathway in the clinical arena.
Despite several attempts, there is no
efficacious drug for prevention of HCC
development in cirrhotic patients. Chronic
administration of interferon failed to show
significant benefits in preventing cancer
development in patients with advanced
fibrosis or cirrhosis (Di Bisceglie et al.,
2008). This disappointing scenario results
from the elementary understanding of theElsevier Inc.key gatekeepers and early molecular
events leading to human hepatocarcino-
genesis and also reflects the lack of an
accurate marker to identify patients at
high risk for HCC development. The
potential role of growth factors in this
process has been highlighted by recent
studies with human and experimental
data. A case-control study found a 4-fold
increased risk of HCC development in
cirrhotic patients with a specific single
nucleotide polymorphism located in the
epidermal growth factor (EGF) gene
(Tanabe et al., 2008). Subsequent experi-
ments showed that this polymorphism
favors EGF stability and, thus, enhances
signaling through the EGF receptor
in vitro. Furthermore, gefitinib, a selective
EGF receptor tyrosine kinase inhibitor,
was able to prevent tumor development
in a chemical-induced model of HCC in
rats (Schiffer et al., 2005). Another growth
factor cascade, the platelet-derived
growth factor (PDGF) pathway, has also
been implicated in the transition from liver
inflammation to HCC. Transgenic mice
overexpressing PDGFR-C adequately
recapitulate the sequence of histological
events that precede HCC in humans (i.e.,
esteatosis, fibrosis, and dysplasia), ulti-
mately developing HCC at 9 months of
age (Campbell et al., 2005) (Figure 1).
The advent of high-throughput genomic
technologies has allowed pinpointing
potential gatekeepers and defining at-risk
populations for tumor recurrence. Two
recent translational studies have under-
scored the role of liver inflammation in
the initiation and dissemination of HCC.
Cancer Cell
PreviewsNORMAL LIVER
~15-20 years ~10 years
CIRRHOSIS
(e.g., Lymphotoxins, IL-6, NF-κB,...) 
Growth Factor Activation
(e.g., EGF, PDGF signaling,...)
HEPATOCELLULAR
CARCINOMA
(WNT activation, 
Proliferation/Cell Cycle,...)
Targets for 
Chemoprevention
Targets for 
Primary Treatment
Viral hepatitis (HBV, HCV)
Alcohol abuse
Hemochromatosis
NASH
Figure 1. Potential Targets of Prevention and Treatment of Hepatocellular Carcinoma
Viral hepatitis and alcohol abuse are the main risk factors for developing chronic liver inflammation leading
to advanced fibrosis and cirrhosis. Once advanced fibrosis has been established, evidence suggests the
implication of inflammatory signals and growth factor cascades in the development of HCC. In this setting,
chemoprevention strategies are expected to target key pro-oncogenic molecules. In established HCC, the
molecular classification of the tumors would allow targeting specific pathways and oncogenic loops in
a more personalized manner.In the first study conducted in more than
300 HCC patients, downstream targets of
interleukin-6 were strongly enriched in
a gene signature able to identify patients
with poor survival after surgical resection
(Hoshida et al., 2008). Prognosis of these
patients was mainly determined by the
occurrence of de novo HCC, suggesting
that the signature was capturing molecular
features related to new primary tumors
arising in an already damaged organ (‘‘field
effect’’). The second study, conducted
mainly on HBV cirrhotic patients, identified
a gene signature correlated to the risk
of developing intrahepatic metastasis
(Budhu et al., 2006). This signature showed
a marked increase in Th2 cytokines,
implying that an anti-inflammatory status
precedes patients with metastatic HCC
(Figure 1). In the current study, lympho-
toxin transgenic mice developed multi-
focal tumors with identical chromosomal
aberrations, indicating clonal spread from
the primary tumor. The implication of this
pathway in intrahepatic dissemination
also suggests that lymphotoxin antago-
nists could play a role in the treatment of
overt HCC. Unfortunately, lymphotoxin
pathway inhibitors, such as baminercept
(Biogen Idec, Cambrigde, MA), have so
far only been tested in inflammatory
diseases (e.g., rheumatoid arthritis).
Different investigators have identified
subgroups of HCC patients based onhomologies in their tumor gene expres-
sion profiles. Among them, samples with
activation of WNT canonical pathway
and those enriched in genes related to
cell cycling and proliferation are common
among different studies. In addition,
genomic data suggest that a subset of
tumors (15%–20%) may have a progen-
itor origin. Interestingly, Haybaeck et al.
observed proliferation of A6+ oval cells
in chronically inflamed lymphotoxin trans-
genic livers. Whether this pathway is rele-
vant to cancer stem cell proliferation
remains to be explored.
From the chemopreventive standpoint,
it is plausible that modulation of the
inflammatory response, (e.g., targeting
IL-6, NF-kB, and lymphotoxin pathways)
along with abrogation of different growth
factor pathways (e.g., EGFR and PDGFR
inhibitors) will be required to counteract
some of the numerous oncogenic signals
present in cirrhotic tissue. In this sense,
an adequate monitoring of side effects
related to new molecular therapies will
be essential. Selection of the appropriate
chemoprevention strategy will depend
on the predominant molecular mecha-
nism of tumor development in a given
patient. Once the tumor has been devel-
oped, integration of the genomic informa-
tion from the tumor and the adjacent
cirrhotic tissue with other clinical variables
will determine patient prognosis andCancer Cell 1guide the therapeutic decision making.
In this sense, data presented by Hay-
baeck et al. provide scientists with a novel
molecular bridge between hepatic inflam-
mation and oncogenesis, opening new
opportunities for selective therapies in
the setting of prevention and treatment
of primary liver cancers.
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